Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK, safety and tolerability of single-dose SAR441344 in healthy Chinese and Japanese adults
jRCT2071220098Phase 1Completed
- Sponsor
- Sanofi
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of frexalimab (2 arms), sponsored by Sanofi. Primary endpoints: Cmax of SAR441344, AUClast of SAR441344 and 1 more. Started Feb 2023; status: completed.
02
Drugs
frexalimab
Beyond the preview
Go deeper on jRCT2071220098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220098.